Less Ads, More Data, More Tools Register for FREE

Pin to quick picksConduit Hldg Regulatory News (CRE)

Share Price Information for Conduit Hldg (CRE)

Share Price is delayed by 15 minutes
Get Live Data
445.00    8.50 (1.95%)
Bid:
444.50
Ask:
445.00
Spread: 0.50 (0.112%)
Market Cap: £658.17m
CRE Live PriceLast checked at - London Stock Exchange

Intraday Conduit Hldg Share Chart

Interim Management Statement

29 Jul 2013 07:00

RNS Number : 3002K
Creston PLC
29 July 2013
 



29 July 2013

 

Creston plc

Interim Management Statement

 

Creston plc ('Creston' or the 'Group') (LSE: CRE), the digitally focused insight and communications group, announces its interim management statement for the period 1 April 2013 to date.

 

Trading update

In the three months to 30 June 2013 (the 'Period'), as expected, revenue is slightly lower than last year with like-for-like revenue 5 per cent lower largely due to the previously announced loss of a client in the Health division. New business activity, however, is currently ahead of expectations and we are encouraged by the potential for this to positively impact revenue in the remainder of the year.

 

Communications

The division's revenue is broadly flat compared with the same period last year. Alongside normal new business activity, there has been substantial time spent on pitching for ten different contracts for the Government Procurement Service. Of these the division has already been awarded a contract for integrated marketing services, which is one of only two such contracts commissioned so far by the Government in its main roster, and we anticipate hearing news of the other pitches in the coming weeks. In the Period, the division has been appointed by Reckitt Benckiser to manage digital activity across its UK brands, by Bentley to manage its events marketing activity, by Sony to manage public relations across its PlayStation brands and the launch of the PlayStation 4, and has also been appointed by Sainsbury's to its digital roster. The full revenue upside from the addition of these new clients will benefit the Group this year.

 

Health

Revenue growth from the Group's UK companies is continuing to replace revenue from Cooney/Waters' contract with Sanofi Pasteur, which came to an end in FY13. The division has reported the expected decline in like-for-like revenue during the first three months compared with the same period last year. With recent joint agency pitches and wins, such as the previously announced global appointment by Gilead Sciences, and international public relations contracts for clients Novartis and Takeda in the Period, the division is well-placed to take advantage of developments in the sector going forward and in particular the increasing demand for digital expertise.

 

Insight

The division has reported an increase in like-for-like revenue compared with the same period last year, highlighting the continued recovery and growth of the division. This has been driven by the additional revenue generated from using innovative research technologies and digital platforms for data collection.

 

Outlook

Although we remain cautious given the potential impact of on-going market volatility on our clients, the Board is pleased with the continuing level of client demand for the digital capabilities of the Group and the increasing focus on cross-agency pitches. We are encouraged by the recent new business wins and are confident that these, added to the continuing high level of new business pitch activity during the Period, will enable the Group to meet the Board's expectations for the full year.

 

Don Elgie, Group Chief Executive of Creston plc, said, "The IPA Bellwether Report on client sentiment towards increased marketing spend is the most encouraging for six years. At Creston we are seeing this being borne out by high levels of new business activity and while opportunities must always be converted, the level of pitching we are seeing is the highest I can remember. Based on our historic pitch to win ratio, we are confident that this will lead to further underlying growth in our client base."

 

 

For further information please contact:

 

Creston plc

+ 44 (0)20 7930 9757

 

Don Elgie, Group Chief Executive

 

 

Barrie Brien, COO/CFO

 

 

Pelham Bell Pottinger

+44 (0)20 7861 3232 

David Rydell/Elly Williamson/ Malika Shermatova

 

About Creston plc

Creston plc (LSE: CRE) is a digitally focused insight and communications group. The Group delivers a range of marketing services, including advertising, brand consultancy, CRM, digital and direct marketing, health communications, local marketing, market research, PR and social media marketing to a broad spectrum of blue-chip global clients. Our insight companies give us a real edge, providing the analytic intelligence to enable us to deliver original thinking that engages audiences, invites participation and influences future trends. www.creston.com

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSEAKXKAEKDEFF
Date   Source Headline
16th May 20254:48 pmRNSDirector/PDMR Shareholding
14th May 20255:57 pmRNSResult of AGM
14th May 20255:51 pmRNSDirector/PDMR Shareholding
14th May 20257:00 amRNSCEO appointment and Directorate Changes
14th May 20257:00 amRNSTrading Update for Q1 2025
6th May 20257:00 amRNSNotice of Q1 2025 Trading Update
22nd Apr 20257:00 amRNSAppointment of Interim CUO
10th Apr 20255:07 pmRNSNotice of AGM
10th Apr 20254:40 pmRNSHolding(s) in Company
10th Apr 20254:39 pmRNSPurchase of Shares by Employee Benefit Trust
9th Apr 20255:49 pmRNSDirector/PDMR Shareholding
9th Apr 20255:33 pmRNSPurchase of Shares by Employee Benefit Trust
8th Apr 20252:59 pmRNSPurchase of Shares by Employee Benefit Trust
7th Apr 20251:28 pmRNSPurchase of Shares by Employee Benefit Trust
4th Apr 20255:27 pmRNSPurchase of Shares by Employee Benefit Trust
4th Apr 20251:21 pmRNSDirector/PDMR Shareholding
3rd Apr 20253:22 pmRNSDirector/PDMR Shareholding
3rd Apr 20253:08 pmRNSPurchase of Shares by Employee Benefit Trust
2nd Apr 20255:10 pmRNSHolding(s) in Company
2nd Apr 20255:09 pmRNSPurchase of Shares by Employee Benefit Trust
1st Apr 20256:20 pmRNSDirector/PDMR Shareholding
31st Mar 20257:00 amRNSCEO Retirement
26th Mar 20255:54 pmRNSDirector/PDMR Shareholding
26th Mar 20255:51 pmRNSDirector/PDMR Shareholding
26th Mar 20255:50 pmRNSDirector/PDMR Shareholding
26th Mar 20255:50 pmRNSDirector/PDMR Shareholding
26th Mar 20255:45 pmRNSDirector/PDMR Shareholding
26th Mar 20255:44 pmRNSDirector/PDMR Shareholding
26th Mar 20255:43 pmRNSDirector/PDMR Shareholding
26th Mar 20255:43 pmRNSDirector/PDMR Shareholding
14th Mar 202512:20 pmRNSNotification of Major Holdings
14th Mar 202512:19 pmRNSNotification of Major Holdings
11th Mar 202512:22 pmRNSNotification of Major Holdings
27th Feb 20258:00 amRNSPublication of 2024 Annual Report and Accounts
25th Feb 20257:00 amRNSDirector/PDMR Shareholding
24th Feb 20257:00 amRNSDirector/PDMR Shareholding
19th Feb 20257:00 amRNSPreliminary results for the year ended 31/12/24
30th Jan 20257:00 amRNSNotice of Results
18th Dec 20247:00 amRNSComment on AM Best ratings outlook
15th Nov 20247:00 amRNSDirector/PDMR Shareholding
13th Nov 20245:35 pmRNSDirector/PDMR Shareholding
8th Nov 20245:16 pmRNSDirector/PDMR Shareholding
8th Nov 20245:16 pmRNSDirector/PDMR Shareholding
8th Nov 20247:00 amRNSDirector/PDMR Shareholding - Amendment
7th Nov 20244:26 pmRNSDirector/PDMR Shareholding
6th Nov 20247:00 amRNSTrading Statement
23rd Oct 20243:02 pmRNSNotice of Results
4th Sep 20243:36 pmRNSDirector/PDMR Shareholding
14th Aug 20247:00 amRNSDirector/PDMR Shareholding
31st Jul 20247:00 amRNSInterim Results for the six months to 30/06/2024

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.